IN2014CN04014A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04014A IN2014CN04014A IN4014CHN2014A IN2014CN04014A IN 2014CN04014 A IN2014CN04014 A IN 2014CN04014A IN 4014CHN2014 A IN4014CHN2014 A IN 4014CHN2014A IN 2014CN04014 A IN2014CN04014 A IN 2014CN04014A
- Authority
- IN
- India
- Prior art keywords
- compounds
- prophylaxis
- modulators
- channels
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2011/052414 WO2012076877A1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
| PCT/GB2012/053045 WO2013083994A1 (en) | 2011-12-06 | 2012-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04014A true IN2014CN04014A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-10 |
Family
ID=47429936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4014CHN2014 IN2014CN04014A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2011-12-06 | 2012-12-06 |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| WO2013182851A1 (en) * | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| CA3110251A1 (en) | 2018-09-21 | 2019-11-28 | Bionomics Limited | Substituted-pyridinyl compounds and uses thereof |
| HUE068686T2 (hu) * | 2018-10-16 | 2025-01-28 | Autifony Therapeutics Ltd | Új vegyületek |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| TWI877067B (zh) | 2018-11-30 | 2025-03-11 | 日商大塚製藥股份有限公司 | 雜環化合物 |
| CA3169057A1 (en) * | 2020-02-06 | 2021-08-12 | Autifony Therapeutics Limited | Kv3 modulators |
| IL310160A (en) | 2021-08-10 | 2024-03-01 | Autifony Therapeutics Ltd | potassium channel modulators |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
| CN117448440B (zh) * | 2023-10-23 | 2024-11-01 | 中国人民解放军空军军医大学 | Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| DK123493D0 (da) * | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
| CN102256968A (zh) * | 2008-12-22 | 2011-11-23 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| AU2010330048B9 (en) * | 2009-12-11 | 2015-02-19 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| BR112012014299A2 (pt) * | 2009-12-14 | 2016-07-05 | Hoffmann La Roche | composto de antivírus heterocíclicos |
| JP5913357B2 (ja) * | 2010-12-06 | 2016-04-27 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤として有用なヒダントイン誘導体 |
| CN103596943B (zh) * | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
-
2012
- 2012-12-06 PL PL12806092.8T patent/PL2788339T3/pl unknown
- 2012-12-06 CN CN201280059633.9A patent/CN103974944B/zh active Active
- 2012-12-06 MX MX2014006753A patent/MX356813B/es active IP Right Grant
- 2012-12-06 CA CA2856654A patent/CA2856654C/en active Active
- 2012-12-06 WO PCT/GB2012/053045 patent/WO2013083994A1/en active Application Filing
- 2012-12-06 KR KR1020147018643A patent/KR20140098850A/ko not_active Ceased
- 2012-12-06 AU AU2012349847A patent/AU2012349847B2/en active Active
- 2012-12-06 DK DK12806092.8T patent/DK2788339T3/en active
- 2012-12-06 EP EP12806092.8A patent/EP2788339B1/en active Active
- 2012-12-06 IN IN4014CHN2014 patent/IN2014CN04014A/en unknown
- 2012-12-06 ES ES12806092.8T patent/ES2576628T3/es active Active
- 2012-12-06 JP JP2014545355A patent/JP5985651B2/ja active Active
-
2014
- 2014-05-14 IL IL232612A patent/IL232612B/en active IP Right Grant
-
2018
- 2018-04-15 IL IL258704A patent/IL258704B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP5985651B2 (ja) | 2016-09-06 |
| HK1203072A1 (zh) | 2015-10-16 |
| CA2856654C (en) | 2020-03-31 |
| MX356813B (es) | 2018-06-13 |
| JP2015502951A (ja) | 2015-01-29 |
| IL258704B (en) | 2019-05-30 |
| CN103974944A (zh) | 2014-08-06 |
| PL2788339T3 (pl) | 2016-09-30 |
| AU2012349847B2 (en) | 2017-02-16 |
| MX2014006753A (es) | 2014-10-15 |
| AU2012349847A1 (en) | 2014-06-26 |
| CN103974944B (zh) | 2016-11-02 |
| EP2788339B1 (en) | 2016-03-09 |
| DK2788339T3 (en) | 2016-05-23 |
| CA2856654A1 (en) | 2013-06-13 |
| ES2576628T3 (es) | 2016-07-08 |
| IL258704A (en) | 2018-06-28 |
| IL232612B (en) | 2018-07-31 |
| IL232612A0 (en) | 2014-06-30 |
| WO2013083994A1 (en) | 2013-06-13 |
| KR20140098850A (ko) | 2014-08-08 |
| EP2788339A1 (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04014A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX338489B (es) | Derivados de hidantoina utiles como inhibidores de kv3. | |
| EP4324527A3 (en) | Formulations of enzalutamide | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| IN2015DN01156A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| PH12014500904B1 (en) | Antibody formulations and methods | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| EA201491894A1 (ru) | Способы лечения непереносимости лактозы | |
| MX359181B (es) | Hidrolizado de colágeno y uso del mismo. | |
| MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| IN2014DN00254A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| EP3449917A3 (en) | Tapentadol for preventing chronification of pain | |
| EA201491522A1 (ru) | Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина | |
| MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| PH12014502075A1 (en) | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours | |
| EA201491291A1 (ru) | АГОНИСТЫ mGlu 2/3 |